DUBLIN, Sept. 23, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "HPAPIs and Cytotoxic Drugs Manufacturing Market, 2014 - 2024" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
The HPAPIs and Cytotoxic Drugs Manufacturing Market, 2014-2024' report provides an extensive study of the rapidly growing manufacturing market of HPAPIs and cytotoxic drugs. Due to their numerous advantages and increased applications in treatment of cancer and other disorders, HPAPIs and cytotoxics have emerged as one of the key focus areas of researchers across the globe. When compared to conventional therapeutic products, these compounds offer multiple advantages. The focus of this report is primarily to understand the likely future evolution of contract manufacturing of HPAPIs and cytotoxics over the next decade.
The report covers various aspects such as analysis of CMOs involved in HPAPI/Cytotoxics manufacturing, pharmaceutical companies with in-house capabilities, regulatory guidelines, key drivers and upcoming opportunities for various stakeholders. Though a few pharmaceutical companies have in-house capabilities, a sizeable proportion of this market is covered by contract manufacturing.
The future growth in the market will primarily be driven by the rapidly expanding market for oncology drugs; majority of the high potency and cytotoxic drugs are being developed for treatment of cancer. With evolving clinical research, use of HPAPIs and cytotoxics in other therapeutic areas such as glaucoma, hormonal imbalances and respiratory disorders have also been identified.
Key Topics Covered:
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. MARKET OVERVIEW
5. HPAPI MANUFACTURING MARKET
6. CYTOTOXIC DRUGS MANUFACTURING MARKET
7. CASE IN POINT: THE ONE STOP SHOPS'
8. MARKET SIZE AND FORECAST
9. PROFILES OF LEADING COMPANIES
10. RECENT DEVELOPMENTS
11. SWOT ANALYSIS
12. EMERGING FOCUS: CONTRACT MANUFACTURING OF ADCs
13. INTERVIEW TRANSCRIPTS
14. CONCLUSION
15. APPENDIX I: Tabulated Data
16. APPENDIX II: List of Companies
Companies Mentioned:
- AAIPharma Services
- AbbVie
- Aesica Pharma
- Agno Pharma
- Alkermes Contract Pharma Services
- Almac
- Alphora Research
- Ampac Fine Chemicals
- AMRI
- Apollo Life Sciences
- Aptuit
- Arch Pharmalabs
- Ash Stevens
- Aspen Holdings
- Asymchem Laboratories
- Azaya Labs
- Baxter Biopharma Solutions
- Bayer
- BioVectra
- Boehringer Ingelheim GmbH
- Bristol Myers Squibb
- Bryllan
- BSP Pharmaceuticals
- Cambrex
- Cambridge Major Labs
- Carbogen Amcis AG (subsidiary of Dishman)
- Catalent Pharma Solutions / Redwood Biosciences
- Cedarburg Pharmaceuticals (AMRI)
- Cerbios Pharma
- ChemCon
- Cipla
- Coldstream Laboratories
- Corden Pharma
- Custom Pharma Services (Dr. Reddy's Laboratories)
- Dr. Reddy's Laboratories
- DSM Pharmaceuticals
- Eisai
- Encap Drug Delivery
- Evonik
- Excella GmbH (now acquired by Fareva)
- Farmabios SpA
- Formex
- GlaxoSmithKline
- GP Pharm
- Haupt Pharma
- Helsinn Advanced Synthesis
- Hikal Ltd.
- Hospira (One to One)
- Idifarma
- IDT Pharma
- ImmunoGen
- Infa, Inc.
- Intas Pharmaceuticals
- IRIX Pharmaceuticals
- Johnson & Johnson (Cilag)
- Johnson Matthey Pharma Services
- Lonza
- Matrix Laboratories Limited
- Medichem
- Merck
- Metrics
- NerPharMa DS
- Neuland Labs
- Novartis (Sandoz)
- Novasep
- Omega
- Omnichem Ajinomoto
- Patheon
- Penn Pharma
- Pfanstiehl
- Pfizer
- Pfizer CentreSource
- Pharmaceuticals (TAPI)
- Pharmatek
- Pierre Fabre Medicament Production
- Piramal Healthcare Pharma Solutions
- Prasfarma
- QS Pharma
- Ranbaxy Laboratories
- Reliable Biopharmaceutical
- Roche
- Rottendorf Pharma
- SAFC
- Saltigo (subsidiary of Lanxess)
- ScinoPharm
- SCM Pharma
- Siegfried
- Stason Pharmaceuticals
- Symbiosis Pharmaceutical
- Synthon Biopharmaceuticals
- TAPI (Teva Pharmaceuticals)
- Uman Pharma
- UPM Pharmaceuticals
- Uquifa
- VUAB Pharma
- VxP Pharma
- WuXi PharmaTech
For more information visit http://www.researchandmarkets.com/research/5zfsrn/hpapis_and
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
